BioSpace News Archive

The retailers have spoken! Sera Labs, Inc., the wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today they have won the coveted Retail Excellence (REX Award) for Natural Products.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a distribution agreement with Mosim, one of China’s leading biopharmaceutical services companies, to distribute MonolixSuite™,

CereHealth Corp., who is known as CereScan, has reached an agreement with Prime Diagnostic Imaging to act as its exclusive provider of quantitative SPECT brain imaging in the Dallas-Ft.

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) announced a cooperative agreement with the Uniformed Services University of the Health Sciences (USU) to work with a team developing guidelines for treating COVID-19 patients.

Kate Farms® Inc., the leader in plant-based, ready-to-use oral and tube feeding nutrition, recently presented new research at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) virtual annual meeting demonstrating improved tolerance, weight gain and adherence in 159 pediatric formula users between the ages of one and 20 years old.

Nucleus Research has opened submissions for the 2021 ROI Awards.

Twin Boro Physical Therapy is pleased to announce the completion of its latest partnership with Pro Staff Physical Therapy, a leading physical therapy operator in Northern New Jersey with nine outpatient clinics offering physical therapy, occupational therapy, and diverse rehabilitative services.

Rithem Life Sciences, a Wilmington, Delaware-based medical device company and developer of safe and efficacious life-saving portable products, has announced the formation of its Board of Directors.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis

Ocugen, Inc., (NASDAQ: OCGN), and Bharat Biotech, a global leader in vaccine innovation, today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.